January 25, 2016

First Patient in United States Treated With Cook Medical's Zenith Alpha Thoracic Device

January 26, 2016—Cook Medical announced the first commercial use of the company’s Zenith Alpha thoracic endovascular graft in the United States. The company announced US Food and Drug Administration approval of the device on September 17, 2015. The first patient was treated in November at The Cleveland Clinic in Cleveland, Ohio.

According to the company, the Zenith Alpha thoracic device, with a 16–20-F delivery system, is indicated for the endovascular treatment of patients with isolated lesions of the descending thoracic aorta (not including dissections) having vascular anatomy suitable for endovascular repair. The Zenith Alpha was developed to provide vascular access and delivery with a lower profile device, which allows physicians to consider thoracic endovascular aortic repair options for patients who otherwise may not have been candidates for larger-profile devices.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

January 25, 2016

First Patient in United States Treated With Cook Medical's Zenith Alpha Thoracic Device

Current Issue

Keep In Touch